Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02589522 : VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Patients with a histologically confirmed diagnosis of non-small cell lung cancer
(NSCLC), including neuroendocrine tumors or small cell lung cancer (SCLC) who are
being evaluated for palliative WBRT (with or without neurosurgical resection or
stereotactic radiosurgery [SRS]) for radiologically or histologically diagnosed brain
metastases presumed to be from the lung cancer are eligible for this Phase I study;
group 2 will only include NSCLC patients

- Life expectance of greater than two months to allow completion of study treatment and
assessment of dose-limiting toxicity

- Group 2 patients should have archived or fresh tumor tissue available from the
non-craniotomy site and will have fresh tumor tissue available from the planned

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

- Leukocytes >= 3,000/mcL

- Absolute neutrophil count (ANC) >= 1,500/mcL

- Platelets >= 100,000/mcL

- If no known liver metastases: total bilirubin < 1.5 x institutional upper limit of
normal (ULN); if known liver metastases, then: total bilirubin < 2.5 x ULN

- If no known liver metastases: aspartate aminotransferase (AST)/serum glutamic
oxaloacetic transaminase (SGOT) < 2 x ULN; if known liver metastases, then: AST/SGOT <
5 x ULN

- Creatinine within normal institutional limits for age OR creatinine clearance >= 60
mL/min/1.73 m^2 for patients with creatinine levels above ULN

- Negative serum or urine pregnancy test result for females of child bearing potential

- Note: Women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to
study entry and for the duration of study participation; should a woman become
pregnant or suspect she is pregnant while she or her partner is participating in
this study, she should inform her treating physician immediately; men treated or
enrolled on this protocol must also agree to use adequate contraception prior to
the study, for the duration of study participation, and 6 months after completion
of VX-970 administration

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients with 1-3 brain metastases, each < 3 cm by contrast MRI, with stable systemic
disease and ECOG score of 0-2, who would otherwise be eligible for SRS/stereotactic
radiation therapy (SRT) alone should not be enrolled into this study unless WBRT is
recommended due to any medical reasons or logistic limitations as determined by the
treating physician; patients who develop recurrence post-SRS/SRT or surgery alone and
are recommended WBRT will be eligible for the protocol

- Presence of diffuse leptomeningeal carcinomatosis (focal/localized involvement is
acceptable), > 1 cm mid-line shift, uncal herniation or significant
hemorrhage/hydrocephalous (small intra-lesional hemorrhage is acceptable); patients
with seizure at presentation who have been started on levetiracetam and have been
stable for 48 hours prior to study registration are eligible at the discretion of
treating physician

- Patients who have received systemic cytotoxic chemotherapy, immunotherapy for 3 weeks
before initiation of planned WBRT or patients who have not recovered from serious
(Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or more) adverse
events from the previously received agents; for oral targeted agents or any other
investigational agents, at least 4 half-lives of the agent (6 weeks for nitrosoureas
or mitomycin C) should have elapsed prior to starting study treatment

- Patients must not have received prior WBRT (previous SRS/SRT done at least 4 weeks
from the planned start of WBRT is acceptable); patients planned upfront to undergo
SRS/SRT/fractionated boosts or neurosurgery after WBRT are not eligible; however,
these treatments/procedures can be performed once the dose limiting toxicity (DLT)
assessment has been completed, if felt clinically necessary

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with VX-970

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to VX-970

- Concomitant administration with strong inhibitors or inducers of cytochrome P450,
family 3, subfamily A, polypeptide 4 (CYP3A4) should be avoided; because the lists of
these agents are constantly changing, it is important to regularly consult a
frequently-updated medical reference for a list of drugs to avoid or minimize use of;
ongoing phenytoin should be either discontinued if clinically safe or transitioned to
non-enzyme-inducing antiepileptics like levetiracetam with a 8-day washout period
(half-life 18-22 hours, time to steady-state 4-8 days) prior to first dose of VX-970
(7-days prior to WBRT)

- Patients needing more than 8 mg dexamethasone per day at the time of start of WBRT
will not be eligible to participate in the study; however, patients will be allowed
entry into the study if it is medically safe to reduce the daily dose of dexamethasone
to 8 mg or less from the day of the start of WBRT; the dexamethasone dose for such
patients may be increased beyond 8 mg per day during the course of treatment if
medically necessary; this increased need for dose should be communicated to the
study's principal investigator, Dr Mohindra at the University of Maryland

- Uncontrolled intercurrent illness that would increase the risk of toxicity or limit
compliance with study requirements; this includes but is not limited to, ongoing
uncontrolled serious infection requiring i.v. antibiotics at the time of registration,
symptomatic congestive heart failure, unstable angina pectoris,
symptomatic/uncontrolled cardiac arrhythmia, or psychiatric illness/social situations
that would limit compliance with study requirements

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible

- Patients with known diagnoses that are associated with germline DDR defects such as Li
Fraumeni syndrome and ataxia telangiectasia are excluded from the study
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557